Shunho Stock Confirms Patent Authorization for Synthetic Nicotine Composition

Regulations by 2FIRSTS.ai
May.08.2024
Shunho Stock Confirms Patent Authorization for Synthetic Nicotine Composition
Shunho shares confirm subsidiary Yunnan Xike's patent approval for synthetic nicotine composition in the US for medical business expansion.

On May 6th, an investor asked a question to Shunho shares (003565) on the interactive platform, "It is rumored that the company's shareholding company Yunnan Xike has been granted authorization for the patent 'Synthetic Nicotine Composition' in the United States. This patented technology will be used to expand into the biopharmaceutical sector. Can you confirm this? Does the company or its subsidiaries have any other strategic plans in the field of synthetic biology?

 

Shunho Stock Confirms Patent Authorization for Synthetic Nicotine Composition
Question and answer details | Image source: Interactive Easy

 

Shunho Corporation stated that its affiliated company, Yunnan Xike Technology Co., Ltd., was granted the invention patent "Synthetic Nicotine Composition" in August 2021, and this patent is still valid. The synthetic nicotine composition covered by this patent technology has the advantages of safety, stability, and ease of storage. It can be used in various fields such as low-temperature HNB products, e-cigarettes, nicotine release patches, pharmaceutical synthesis, etc.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Advocates say the economic authority’s decision contradicts national health goals and violates a Supreme Court directive banning new tobacco ventures.
Oct.27 by 2FIRSTS.ai
COP11 Concludes with Major Decisions on Global Tobacco Control
COP11 Concludes with Major Decisions on Global Tobacco Control
The Eleventh Session of the Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (FCTC) concluded in Geneva on November 22, with 160 Parties adopting major decisions on tobacco and nicotine regulation, environmental protection, sustainable financing, and tobacco industry liability. A landmark decision mandates a complete ban on the use and sale of tobacco and all novel nicotine products across all UN premises worldwide.
Nov.24 by 2FIRSTS.ai
Australia TGA Warns Delivery Platforms: Don’t Promote or Supply Vapes Illegally
Australia TGA Warns Delivery Platforms: Don’t Promote or Supply Vapes Illegally
The Therapeutic Goods Administration (TGA) warned online delivery platforms not to breach Australian vape laws and said it worked with two major companies to remove non-compliant material. Under the Therapeutic Goods Act 1989, advertising vapes to the public is banned and sales are pharmacy-only; tobacconists and convenience stores cannot supply vapes. TGA will continue enforcement, with severe penalties for breaches.
Oct.30 by 2FIRSTS.ai
Following Japan debut, IQOS ILUMA i “Seletti Edition” limited series launches in South Korea.
Following Japan debut, IQOS ILUMA i “Seletti Edition” limited series launches in South Korea.
Philip Morris International (PMI) Korea announced a collaboration with Italian design brand Seletti to launch the IQOS ILUMA i limited “Seletti Edition.” Pre-sales begin on the 29th at IQOS.com for IQOS Club Gold and Platinum members, with sales from the 30th via the website and nine IQOS-owned stores nationwide. PMI previously said the series would debut in Japan first before rolling out to 13 global travel-retail markets.
Oct.29 by 2FIRSTS.ai
Research Report: E-Cigarette Device Market to Hit $34.29 Billion by 2031; Top Brands Now Hold Nearly Half the Share
Research Report: E-Cigarette Device Market to Hit $34.29 Billion by 2031; Top Brands Now Hold Nearly Half the Share
Market research firm LP Information has released a global e-cigarette market report forecasting that the e-cigarette device market—including both disposable and reusable devices—will reach US$34.29 billion by 2031, with a 9.4% CAGR from 2025 to 2031.
Oct.16
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.
Nov.24 by 2FIRSTS.ai